Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dienestrol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dienestrol SCHEMBL52170 | 1.00 | ESR1 (1.00) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL2896853 | 1.00 | ESR1 (1.00) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL9317394 | 0.97 | ESR1 (0.94) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL3716190 | 0.95 | ESR1 (0.90) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL8425094 | 0.92 | ESR1 (0.85) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL6573104 | 0.92 | ESR1 (0.85) | ESR1MAPTLMNAHSD17B10MEN1 | |
| SCHEMBL13492676 | 0.90 | MAPT (0.81) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL114016 | 0.90 | ESR1 (0.81) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL8854079 | 0.84 | ESR1 (0.71) | ESR1MAPTLMNAHSD17B10MEN1 | |
| SCHEMBL15721373 | 0.84 | MAPT (0.71) | ESR1MAPTLMNAHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633382-B2 | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen | PARACRINE THERAPEUTICS AB (SE) | 2023-04-25 | — | — | US | disclosed |
| US-20210186932-A1 | TREATMENT OF ER-NEGATIVE BREAST CANCER WITH AN PDGF-CC INHIBITOR AND ANTI-ESTROGEN | PARACRINE THERAPEUTICS AB (SE) | 2021-06-24 | — | — | US | disclosed |
| US-20200030259-A1 | Antiestrogens and/or Aromatase Inhibitors for Use in Treating Obesity and Related Symptoms | REPROS THERAPEUTICS INC (US) | 2020-01-30 | — | — | US | disclosed |
| EP-3515424-A1 | ANTIESTROGENS AND/OR AROMATASE INHIBITORS FOR USE IN TREATING OBESITY AND RELATED SYMPTOMS | Repros Therapeutics Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| EP-2819676-B1 | COMBINATION THERAPY FOR TREATING ANDROGEN DEFICIENCY | REPROS THERAPEUTICS INC (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2018058032-A1 | ANTIESTROGENS AND/OR AROMATASE INHIBITORS FOR USE IN TREATING OBESITY AND RELATED SYMPTOMS | REPROS THERAPEUTICS INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-9687458-B2 | Trans-clomiphene for use in cancer therapy | REPROS THERAPEUTICS INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150283099-A1 | Trans-Clomiphene for Use in Cancer Therapy | REPROS THERAPEUTICS INC. (US) | 2015-10-08 | — | — | US | disclosed |
| EP-2914294-A1 | TRANS-CLOMIPHENE FOR USE IN CANCER THERAPY | Repros Therapeutics Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150031656-A1 | COMBINATION THERAPY FOR TREATING ANDROGEN DEFICIENCY | REPROS THERAPEUTICS INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-8377991-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8372887-B2 | Trans-clomiphene for metabolic syndrome | REPROS THERAPEUTICS INC. (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2211848-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | Repros Therapeutics Inc. (US) | 2010-08-04 | — | — | EP | disclosed |
| US-7737185-B2 | treating wasting in a hypogonadal male with chronic obstructive pulmonary disorder, especially a loss of muscle mass; reducing side effects while elevating serum testosterone levels | REPROS THERAPEUTICS INC. (US) | 2010-06-15 | — | — | US | disclosed |
| WO-2010054248-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME AND DIABETES MELLITUS TYPE 2 | REPROS THERAPEUTICS INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2009051908-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099265-A1 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME | REPROS THERAPEUTICS INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008147640-A2 | HORMONE REPLACEMENT THERAPY | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293683-A1 | Hormone Replacement Therapy | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293683-A1 | Hormone Replacement Therapy | ESR2, SHBG, ESRRG | ESR1 4/4885MAPT 3889/4885LMNA 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.